HomeArticlesClinicalEffectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study
ClinicalMS

Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study

Source:Wiley
Published:2025

Summary

This study provides strong evidence that autologous hematopoietic stem cell transplantation offers superior long-term clinical outcomes compared to two of the most effective current disease-modifying therapies for relapsing multiple sclerosis, particularly in terms of preventing relapses and maintaining sustained clinical benefit over a 5-year follow-up period.

Access Original Research

View the complete study and detailed methodology from the original source.

Read Full Study →

Related Articles

Autologous mesenchymal stem cells offer a new paradigm for salivary gland regeneration

Over 60% of patients receiving treatment for head and neck cancers experience radiation-induced salivary gland damage. The study suggests this could provide a definitive treatment rather than just symptom management for the millions of people suffering from dry mouth conditions.

Nature2023
Read More

Randomized controlled study for the anti-aging effect of human adipocyte-derived mesenchymal stem cell media combined with niacinamide after laser therapy

The combination of stem cells and niacinimide improved skin through multiple mechanisms - reducing inflammation, protecting collagen structure, promoting collagen production, and enhancing skin repair - resulting in measurable improvements in wrinkles, pigmentation, and overall skin appearance that both patients and doctors could observe.

PubMed2021
Read More

Innovative method of alopecia treatment by autologous adipose-derived SVF

Hair density and keratin significantly increased after one injection of stem cells.

PubMed Central2021
Read More